logo-loader
viewHelix BioPharma Corp.

Helix Biopharma starts enrolling next cohort in Poland

Helix BioPharma (TSE:HBP),which is developing candidates for preventing and treating cancer, has started enrolling the next cohort under its phase I/II clinical study.

test-tubes.jpg
L-DOS47 is currently being evaluated in two clinical studies - Poland and in the US- as a treatment for certain patients with non-small cell lung cancer...

Helix BioPharma (TSE:HBP),which  is developing candidates for preventing and treating cancer, has started enrolling the next cohort under its phase I/II clinical study.

It is now screening patients for the 15th dose level cohort in the ongoing study for safety, tolerability and preliminary efficacy L-DOS47 in Poland.

L-DOS47 is currently being evaluated in two clinical studies - Poland and in the US- as a treatment for certain patients with non-small cell lung cancer.

The Trial Steering Committee has completed the safety review of cohort 14 and recommended that Helix begin enrollment of patients into the fifteenth (15) cohort.

Quick facts: Helix BioPharma Corp.

Price: 0.88 CAD

TSX:HBP
Market: TSX
Market Cap: $116.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Helix BioPharma Corp. named herein, including the promotion by the Company of Helix BioPharma Corp. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Helix BioPharma closes financing as they look to uplist to...

Helix BioPharma (TSE: HBP) CEO Dr Heman Chao sat down with Steve Darling from Proactive in New York to share details they have just completed a fundraise. Chao also talked about his desire to uplist the company to the Nasdaq.  Dr Chao also told Proactive what is planned this year in the...

on 6/2/20

2 min read